Epizyme Inc (EPZM)
CHAIKIN MONEY FLOW
Trading: SELL @ $7.53
Signal Strength: MEDIUM
Epizyme Inc (NASDAQ:EPZM) current price has highlighted recent selling pressure and the continuation of a bearish trading conditions. Currently, the CMF is -0.08. EPZMThe bearish signal has been active for 0 day. During the quarter, the lowest CMF value was -0.3 occurring on the Sep 21 2018.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading exit. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
Developed by Marc Chaikin, Chaikin Money Flow measures the amount of Money Flow Volume over a specific period. Money Flow Volume forms the basis for the Accumulation Distribution Line. Instead of a cumulative total of Money Flow Volume, Chaikin Money Flow simply sums Money Flow Volume for a specific look-back period, typically 20 or 21 days. The resulting indicator fluctuates above/below the zero line just like an oscillator. Chartists weigh the balance of buying or selling pressure with the absolute level of Chaikin Money Flow. Chartists can also look for crosses above or below the zero line to identify changes on money flow.
Calculation: Chaikin Money Flow (20):
1) Money Flow Multiplier = [(Close - Low) - (High - Close)] / (High - Low);
2) Money Flow Volume = Money Flow Multiplier x Volume for the Period;
3) 20-period CMF = 20-period Sum of Money Flow Volume / 20 period Sum of Volume;
PROFILE: Epizyme Inc (EPZM)
Stock Exchange: NASDAQ
Company: Epizyme Inc
Ticker Codes: | EPZM | NASDAQ:EPZM |
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Chaikin Money FlowDownload
No data available.